KYMR logo

Kymera Therapeutics (KYMR)

Profile

Full Name

Kymera Therapeutics, Inc.

Ticker Symbol

KYMR

Exchange

NASDAQ

Country

United States

IPO

August 21, 2020

Indexes

Not included

Employees

188

Key Details

Price

$25.60(+2.32%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$47.07M(-40.11% YoY)

Annual EPS

-$2.98(-18.25% YoY)

PE ratio

-

Next earnings date

May 2, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 13, 25 Citigroup
Buy
Feb 28, 25 HC Wainwright & Co.
Buy
Jan 21, 25 Stephens & Co.
Overweight
Dec 27, 24 Leerink Partners
Outperform
Dec 10, 24 BTIG
Buy
Dec 6, 24 BMO Capital
Market Perform
Dec 2, 24 Wells Fargo
Overweight
Nov 18, 24 Stephens & Co.
Overweight
Nov 6, 24 Morgan Stanley
Equal-Weight
Nov 4, 24 UBS
Buy

Institutional Ownership

  • What is the ticker symbol for Kymera Therapeutics?
  • Does Kymera Therapeutics pay dividends?
  • What sector is Kymera Therapeutics in?
  • What industry is Kymera Therapeutics in?
  • What country is Kymera Therapeutics based in?
  • When did Kymera Therapeutics go public?
  • Is Kymera Therapeutics in the S&P 500?
  • Is Kymera Therapeutics in the NASDAQ 100?
  • Is Kymera Therapeutics in the Dow Jones?
  • When was Kymera Therapeutics's last earnings report?
  • When does Kymera Therapeutics report earnings?
  • Should I buy Kymera Therapeutics stock now?

What is the ticker symbol for Kymera Therapeutics?

The ticker symbol for Kymera Therapeutics is NASDAQ:KYMR

Does Kymera Therapeutics pay dividends?

No, Kymera Therapeutics does not pay dividends

What sector is Kymera Therapeutics in?

Kymera Therapeutics is in the Healthcare sector

What industry is Kymera Therapeutics in?

Kymera Therapeutics is in the Biotechnology industry

What country is Kymera Therapeutics based in?

Kymera Therapeutics is headquartered in United States

When did Kymera Therapeutics go public?

Kymera Therapeutics's initial public offering (IPO) was on August 21, 2020

Is Kymera Therapeutics in the S&P 500?

No, Kymera Therapeutics is not included in the S&P 500 index

Is Kymera Therapeutics in the NASDAQ 100?

No, Kymera Therapeutics is not included in the NASDAQ 100 index

Is Kymera Therapeutics in the Dow Jones?

No, Kymera Therapeutics is not included in the Dow Jones index

When was Kymera Therapeutics's last earnings report?

Kymera Therapeutics's most recent earnings report was on Feb 27, 2025

When does Kymera Therapeutics report earnings?

The next expected earnings date for Kymera Therapeutics is May 2, 2025

Should I buy Kymera Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page